Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Metformin|DRUG: Erlotinib
Sponsor: Columbia University
Collaborators: Susan G. Komen Breast Cancer Foundation|Astellas Pharma Inc